Lexaria Bioscience (LEXX) Total Liabilities (2011 - 2026)
Lexaria Bioscience (LEXX) posted Total Liabilities of $437091.0 for Q2 2026, up 57.8% sequentially from $276997.0 in Q1 2026, and down 72.25% YoY from $1.6 million in Q2 2025.
Lexaria Bioscience (LEXX) Total Liabilities (2011 - 2026) Analysis & Trends
Lexaria Bioscience has reported Total Liabilities for 16 years, with the latest figure at $437091.0 in Q2 2026.
- Quarterly Total Liabilities fell 72.25% year-over-year to $437091.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $437091.0 (down 72.25% YoY) and the FY2025 annual result came in at $1.6 million, up 30.08% from the prior year.
- Total Liabilities advanced to $437091.0 in Q2 2026 per LEXX's latest filing, from $276997.0 in the prior quarter.
- Over five years, Total Liabilities peaked at $1.9 million in Q1 2025 and troughed at $194623.0 in Q1 2022.
- A 5-year average of $687322.4 and a median of $340619.0 in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities soared 838.67% in 2025, then sank 85.55% in 2026.
- Over 5 years, Total Liabilities stood at $281520.0 in 2022, then declined by 9.76% to $254040.0 in 2023, then soared by 57.34% to $399718.0 in 2024, then surged by 282.11% to $1.5 million in 2025, then sank by 71.38% to $437091.0 in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $437091.0, $276997.0, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 10.03 Bn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 437,091.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 437,091.00 |
| Feb 28, 2026 | 276,997.00 |
| Nov 30, 2025 | 1.53 Mn |
| Aug 31, 2025 | 1.57 Mn |
| May 31, 2025 | 1.57 Mn |
| Feb 28, 2025 | 1.92 Mn |
| Nov 30, 2024 | 399,718.00 |
| Aug 31, 2024 | 1.21 Mn |
| May 31, 2024 | 271,375.00 |
| Feb 29, 2024 | 204,203.00 |
| Nov 30, 2023 | 254,040.00 |
| Aug 31, 2023 | 403,908.00 |
| May 31, 2023 | 1.20 Mn |
| Feb 28, 2023 | 223,131.00 |
| Nov 30, 2022 | 281,520.00 |
| Aug 31, 2022 | 201,437.00 |
| May 31, 2022 | 225,165.00 |
| Feb 28, 2022 | 194,623.00 |
| Nov 30, 2021 | 277,328.00 |
| Aug 31, 2021 | 203,265.00 |